The BP26-OMP16Es Nanoparticle Vaccine Elicits Protective Immunity against Brucella
ACS Nano · 2026
DOI: 10.1021/acsnano.6c11565 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Yunyi Zhai und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Northwest A&F University, Yangling712100, China. Hauptthemen laut MEDLINE: Nanoparticles, Brucellosis, Brucella, Brucella Vaccine. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China.
Abstract (Originalsprache)
Brucellosis, a major global zoonosis causing over 2.1 million human infections annually, poses a significant threat to public health and livestock economies. Conventional vaccines face substantial limitations, including residual virulence and diagnostic interference in live attenuated vaccines, and poor immunogenicity in subunit vaccines. To address these issues, we developed BP26-OMP16Es, a self-assembling nanoparticle vaccine constructed by fusing immunodominant B- and T-cell epitopes from OMP16 to the self-assembling antigen BP26 via flexible linkers, yielding single-copy (1×) and double-copy (2×) epitope tandem nanoparticles. These particles formed homogeneous, barrel-shaped structures (14–23 nm) with strong immunoreactivity against Brucella-specific antibodies. In murine models, the vaccine elicited potent humoral and cellular immune responses, characterized by high antibody titers, enhanced IFN-γ+ CD8+ T cell proliferation, a balanced Th1/Th2 profile, and the induction of immunological memory for durable protection. Immune sera also mediated effective clearance of infected macrophages via antibody-dependent cellular cytotoxicity (ADCC). Challenge experiments confirmed that the vaccine significantly reduced splenic Brucella burden and alleviated pathological damage, with the 2× construct offering superior protection. In summary, this study integrates self-assembling nanotechnology with a multiepitope strategy to create a safe and potent vaccine platform. The 2× design enhances epitope density, boosting immunogenicity and conferring solid protection against Brucella infection. This approach provides valuable insights for developing vaccines against brucellosis and other intracellular pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Northwest A&F University, Yangling712100, China.
- Key Laboratory of Animal Biotechnology, Ministry of Agriculture and Rural Affairs, Yangling712100, China.
- Engineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Yangling712100, China.
ORCID-Profile: Aihua Wang
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
Zitieren
APA
Zhai, Y., Sun, K., Wudong, G., Yuan, Y., Tang, T., Zhou, D., Lin, P., Liu, W., Jin, Y., & Wang, A. (2026). The BP26-OMP16Es Nanoparticle Vaccine Elicits Protective Immunity against Brucella. ACS Nano. https://doi.org/10.1021/acsnano.6c11565
Vancouver
Zhai Y, Sun K, Wudong G, Yuan Y, Tang T, Zhou D, et al. The BP26-OMP16Es Nanoparticle Vaccine Elicits Protective Immunity against Brucella. ACS Nano. 2026. doi:10.1021/acsnano.6c11565
BibTeX
@article{Zhai2026,
author = {Zhai, Yunyi and Sun, Kaihui and Wudong, Gaowa and Yuan, Ye and Tang, Ting and Zhou, Dong and Lin, Pengfei and Liu, Wei and Jin, Yaping and Wang, Aihua},
title = {The BP26-OMP16Es Nanoparticle Vaccine Elicits Protective Immunity against Brucella},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c11565}
}
EUVIMED